/PRNewswire/ Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing.
Nuvo Group Receives 510(k) FDA Clearance for Remote Monitoring of Uterine Activity
USA - English
News provided by
Share this article
Share this article
TEL AVIV, Israel, June 10, 2021 /PRNewswire/ Nuvo Group a private company commercializing INVU by Nuvo™, an FDA-cleared, patent-protected, prescription-initiated remote pregnancy monitoring platform today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to add a new uterine activity module that provides capability for remote monitoring of uterine activity (UA). With this clearance, INVU can provide a reliable, passive alternative to existing methods of UA measurement. INVU uses only external sensors, allowing it to be used without any invasive component or the need for an in-hospital or in-clinic procedure.
Share this article
Share this article
HONG KONG, June 10, 2021 /PRNewswire/ CBMG Holdings (or the Company ), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced early promising safety and efficacy results of C-CAR066, a novel second generation chimeric antigen receptor T (CAR-T) therapy targeting CD20 antigen in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) that has failed to an anti-CD19 CAR-T therapy. Patients who fail anti-CD19 CAR-T therapy generally have a dismal prognosis and are an important group with high unmet medical needs. This abstract was recently presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by the Principal Investigator (PI) of the study, Aibin Liang, M.D., Professor of Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, China.
/PRNewswire/ Today AllyAlign Health (AAH), a Medicare Advantage insurance company that is improving the health and wellbeing of residents of senior housing.
/PRNewswire/ Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced that it has appointed.